Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02094625 · ClinicalTrials.gov registry record · Phase 1
NAC to Prevent Cisplatin-induced Hearing Loss
A Phase 1 study, sponsored by Children's Hospital Los Angeles.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT02094625 is a Phase 1 study that has completed, run by Children's Hospital Los Angeles. The registered enrollment target is 52 participants.
The verdict
NCT02094625, a Phase 1 study, has completed, sponsored by Children's Hospital Los Angeles.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
Cisplatin is a key chemotherapy agent for the treatment of multiple childhood cancers but causes permanent hearing loss. This study investigates the drug N-acetylcysteine (NAC) to determine the dose necessary to protect hearing and also how well tolerated NAC is when combined with chemotherapy.
Interventions
- DRUG N-Acetylcysteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2016-03 |
| Est. Completion | 2021-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02094625
The ClinicalTrials.gov registry entry for NCT02094625 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Los Angeles, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which N-Acetylcysteine is the first listed.
NCT02094625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02094625 about?
NCT02094625 is a clinical study titled "NAC to Prevent Cisplatin-induced Hearing Loss". Cisplatin is a key chemotherapy agent for the treatment of multiple childhood cancers but causes permanent hearing loss. This study investigates the drug N-acetylcysteine (NAC) to determine the dose necessary to protect hearing and also how well tolerated NAC is when combined with chemotherapy.
What is the current status of trial NCT02094625?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2016-03. Estimated completion is 2021-08.
What interventions are being tested in trial NCT02094625?
The interventions under investigation include: N-Acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT02094625?
This trial is sponsored by Children's Hospital Los Angeles, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.